Preclinical studies have shown that blocking IL-6 receptor enhances the therapeutic effect of programmed cell death ligand 1 (PD-L1) and inhibiting IL-6 expression exhibited promise in suppressing pancreatic cancer progression (93–95). Here, IL6 is linked to familial pancreatic carcinoma.